2seventy Bio, Inc. expected revenue from Abecma (idecabtagene vicleucel) and its $307m in cash as of 30 June to fund its operations into 2026. But with multiple issues impacting sales of its Bristol Myers Squibb Company-partnered product and delays for the T-cell therapy maker’s two clinical-stage programs, 2seventy is restructuring to ensure its cash lasts into at least 2026, with cutbacks that include a 40% workforce reduction, a slowdown in internal R&D and a move to partner more of its programs.
2Seventy Cuts Jobs As It Streamlines Pipeline, Focuses On Abecma
CEO Nick Leschly Stepping Down, Remaining As Chairman
Nearly two years after its spin-out from bluebird, 2Seventy is slowing in-house R&D and leaning on partners to conserve cash while BMS-partnered Abecma regains its competitive footing.
More from Strategy
• By
Plus deals involving GV20/Mitsubishi Tanabe, Kaken/Alumis, AstraZeneca/Alteogen and deal terminations involving Clover/Gavi Alliance and Rhythm/RareStone.
• By
The head of the Spanish medical dermatology specialist told Scrip that maintaining the status quo will only result in the continent’s life sciences sector slipping further behind the US and China.
• By
Stakeholders are pleading for newly confirmed FDA Commissioner Martin Makary to stand up for the agency's high scientific standards and staff as he begins his term.
• By
Plus deals involving Relmada/Trigone, Alvotech/Xbrane, OPKO Health/Entera, iOncologi/TargImmune and more.
More from Business
• By
Stakeholders are pleading for newly confirmed FDA Commissioner Martin Makary to stand up for the agency's high scientific standards and staff as he begins his term.
• By
Plus deals involving Relmada/Trigone, Alvotech/Xbrane, OPKO Health/Entera, iOncologi/TargImmune and more.
• By
With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.